A Type IA variation to an EAEU dossier is filed within 365 days after implementation. When the application must go in first
A Type IA variation (a minor variation with minimal or no impact on the quality, safety and efficacy of the medicinal product) follows the «do and tell» rule: the application is filed within 365 calendar days of the date the variation is implemented. The exception covers variations that lead to a revision of the product information or affect the data in the Union’s unified register of registered medicines. The application for such variations is filed before implementation, and they are implemented after the data enter the register. This is set out in the Rules for Making Variations to the Registration Dossier of a Registered Medicinal Product for Medical Use, which form part of the Rules for Registration and Regulatory Review of Medicines for Medical Use (Decision of the Council of the Eurasian Economic Commission (EEC) No. 78 of 3 November 2016; hereinafter the Variation Rules).
An application for notification-type variations (Type IA and Type IAIN, that is, Type IA with immediate notification) is rejected if the dossier contains variations that are not listed in the application and are not notification-type. The decision to reject is taken by the authorized body of the reference state (the member state whose body conducts the procedure) in up to 20 working days.
The state fee for a variation under Union rules is RUB 5,000 without regulatory review and RUB 150,000 with regulatory review (under the Tax Code of the Russian Federation).
Procedure under 61-FZ and procedure under the Variation Rules
Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (hereinafter 61-FZ) sets the national procedure for making variations to the registration dossier documents. The decision on whether to conduct a regulatory review is taken according to the classification of variations approved by the authorized federal executive body. The decision on the variation is taken in up to 50 working days if a regulatory review of quality and (or) of the ratio of expected benefit to possible risk is needed, and in up to 10 working days in other cases.
EEC Council Decision No. 78 of 3 November 2016 «On the Rules for Registration and Regulatory Review of Medicines for Medical Use» provides that variations to dossiers formed under the legislation of member states are made under that legislation no later than 31 December 2025. It does not define the procedure after that date. Letter of the Russian Ministry of Health No. 25-6/894 of 29 January 2026 describes the validity period of registration certificates issued under national rules and does not address the procedure for making variations to the dossier.
The Variation Rules apply to products registered under the Rules for Registration and Regulatory Review and to products whose dossiers are undergoing dossier alignment with these Rules. For a product registered in more than one member state, the rules for several states apply; for a product registered in one member state, separate rules for a single state apply.
Table 1 compares the procedure, deadlines and state fees under the two acts. The classification and codes of variations apply in the version of EEC Council Decision No. 93 of 26 November 2025, so codes and conditions from earlier materials are checked against the current text.
Table 1. Procedure under 61-FZ and under the Variation Rules
| Parameter | 61-FZ | Variation Rules |
|---|---|---|
| Division of variations | With and without regulatory review, according to the classification of the authorized body | Five categories: Type IA, Type IAIN, Type IB, Type II and registration extension |
| Deadline | Decision within 10 working days without regulatory review and within 50 with regulatory review | Decision on Type IA and IAIN within 20 working days, regulatory review of Type IB up to 30 working days, of Type II up to 60 |
| State fee | RUB 5,000 and RUB 490,000 (under the Tax Code of the Russian Federation) | RUB 5,000 and RUB 150,000 (under the Tax Code of the Russian Federation) |
Five categories of variations and how to tell them apart
The Variation Rules contain the definitions of the categories, the list of registration extensions, the general classification of Type IA and Type II variations, and the codes of specific variations.
Table 2. Categories of variations under the Variation Rules
| Category | What it is | Procedure | Deadline |
|---|---|---|---|
| Type IA | A variation with minimal or no impact on quality, safety and efficacy | Notification without regulatory review («do and tell») | Application within 365 calendar days of implementation; before implementation if the variation revises the product information or affects the data of the unified register |
| Type IAIN | Type IA that requires immediate notification | Notification without regulatory review | 20 working days from the date of implementation |
| Type IB | A variation that is not Type IA, Type IAIN or Type II and is not a registration extension | Regulatory review | Up to 30 working days, up to 60 when grouped |
| Type II | A variation that may significantly affect the quality, safety or efficacy of the product | Regulatory review | 60 working days, up to 80 for indications and when grouped |
| Registration extension | Variations from the list of registration extensions | Requires a new registration | The application is filed simultaneously in the reference state and in all interested member states |
The conditions for Type IA are set separately for each code in the classification of variations.
If at least one condition is not met, the variation may be filed as Type IB (the rules call this «Type IB by default») if either of two conditions is met:
the classification of variations or the recommendation of the authorized body does not classify the variation as Type II;
the applicant does not consider that the variation may significantly affect the quality, safety and efficacy of the product.
If the authorized body, while reviewing the application, decides that such a variation may significantly affect quality, safety or efficacy, it may classify the variation as Type II and request a change of the application type. The deadline is then counted under the rules for Type II from the date the reply to the request is received.
If the classification of a variation cannot be determined even with the recommendation of the authorized body, it is classified as Type II under one of two conditions: the applicant sent a reasoned request when filing, or the body decided after assessing the application that the variation significantly affects quality, safety or efficacy. In all other cases such a variation is filed as Type IB by default.
Before filing, the registration holder may request a classification recommendation from the authorized body (expert organization) of the reference state. This body sends the recommendation in up to 30 working days, and if it consults the Expert Committee for Medicines, the period is extended by a further 30 working days.
The general classification assigns the following variations to Type II:
a new indication or a change to an existing one;
significant changes to the summary of product characteristics (SmPC), especially on new data on quality, results of preclinical or clinical studies, or pharmacovigilance data;
variations beyond the range, limits or acceptance criteria of the approved specifications (the normative document on quality);
significant changes to the manufacturing process, composition, specifications or impurity profile of the active pharmaceutical ingredient (API) or of the product that may significantly affect quality, safety or efficacy;
changes to the manufacturing process or manufacturing sites of the API of a biological product;
a new design space (ranges of process parameters within which changes need no separate approval) or an extension of an approved one, if it is developed under Union guidelines or international scientific guidelines;
a change to the API of a seasonal, pre-pandemic or pandemic influenza vaccine for humans.
The list of registration extensions in the Variation Rules names the following:
replacement of the API: another salt, an isomer, a biological API with a changed molecular structure and other cases given in the list;
a change in bioavailability, pharmacokinetics, dosage, dosage form or route of administration.
All variations from this list are registration extensions, and variations outside the list are not considered extensions. When a new dosage form is added, a registration certificate with a new number is issued.
Conditions of individual variation codes
Each code has its own conditions and its own set of documents, so the conditions and documents are checked against the code itself (table 3). The code letters are given in Latin transliteration of the Cyrillic letters used in the Rules (for example, V stands for В and B for Б).
Table 3. Selected codes of the classification of variations
| Variation | Code | Type | What to check |
|---|---|---|---|
| Change of name or address of the registration holder | A.1a | IAIN | The holder remains the same legal entity; there is a document from the authority of the country where the legal entity is registered (for example, a tax authority) and revised product information |
| Transfer of the registration certificate to another legal entity | A.1b | IAIN | Documents on the basis for the transfer, a revised summary of the pharmacovigilance system or a revised pharmacovigilance system master file (if included in the dossier), information on the organization responsible for complaints in the Union, a document from the new holder confirming that there are no other changes to the product information |
| Change of the trade name of a product registered under the Rules for Registration and Regulatory Review | A.2a | IAIN | Confirmation by the authorized body (expert organization) of the reference state that the new name is acceptable; the applicant’s justification and revised product information |
| Change of name or address of the manufacturer that releases batches | A.5a | IAIN | The site and manufacturing processes do not change |
| Change of name or address of the manufacturer that does not release batches | A.5b | IA | The same conditions |
| Correction of typos and technical errors | A.9 | IAIN or IB | IAIN if the correction affects the product information, IB if it does not; a justification of the technical nature of the error is needed |
| Replacement or addition of a site for batch quality control (testing) | B.II.b.2a | IA | The site is licensed in the country of manufacture; the product is not biological; analytical methods have been successfully transferred to the new laboratory |
| Replacement or addition of the manufacturer responsible for batch release | B.II.b.2v | IAIN | The site is licensed in the country of manufacture; if batch quality control is included, the product is not biological. For a biological product with a biological test method the type is II |
| Change to the SmPC, package leaflet or packaging mock-ups at the requirement of an authority conclusion or request | V.I.1 | IAIN, IA or II | IAIN if the dossier is under regulatory review; IA if the dossier was not submitted for regulatory review and the holder has provided no new data; II if new data are provided |
| Clarification of storage conditions during use of the product | V.I.14 | IB | Results of real-time stability studies |
Deadlines by variation type
The procedure involves the reference state (the member state whose body conducts the regulatory review of the variation) and the states of recognition (the member states whose bodies decide on making the variation after the decision of the reference state). The reference body works within the deadlines set for a product registered in several member states (table 4).
Table 4. Deadlines of the reference body for a product registered in several member states
| Stage | Type IA and IAIN | Type IB | Type II |
|---|---|---|---|
| Assessment of documents | Decision to approve or reject no later than 20 working days from receipt of the documents | 5 working days to assess completeness, composition and formatting | 5 working days to assess completeness, composition and formatting |
| Request to the applicant | The reference body may request missing documents within 5 working days | Request within 5 working days after the assessment; the applicant’s reply takes up to 90 working days, and this time is not counted in the regulatory review period | Request within 5 working days after the assessment; the applicant’s reply takes up to 90 working days, and this time is not counted in the regulatory review period |
| Regulatory review | Not conducted | Up to 30 working days, up to 60 when grouped | 60 working days, up to 80 for indications and when grouped; the reference body may shorten the period if the variation is urgent |
| Decision after regulatory review | Not applicable | 5 working days from receipt of information from the last of the states of recognition | 10 working days from receipt of the updated assessment report or reasoned position |
The authorized body of a state of recognition decides on Type IA and IAIN within 15 working days from receipt of the application and access to the dossier materials. For Type IB it decides within 10 working days after receiving information on the positive decision of the reference state. For Type II it decides on recognition of the assessment report within 10 working days and on making the variation within a further 10 working days.
The application to the bodies of the states of recognition for Type IB and II is filed within 10 working days after filing in the reference state. For Type IA and IAIN that do not revise the product information and do not affect the data of the unified register, this application is filed within 20 working days after approval by the reference body. If Type IA or IAIN revise the product information or affect the data of the unified register, the application is filed simultaneously with all bodies where the product is registered.
For a product registered in one member state, the decision period for Type IA and IAIN is 20 working days, which can be extended to 80 working days for multiple grouped variations. Regulatory review of Type IB takes up to 30 working days and can be extended to 60.
A Type IA variation that does not affect the product information may be implemented at any time before the procedure is completed. Type IB, Type II and variations that revise the product information may be implemented after a positive decision of the reference body. If a variation changes the data in the registration certificate, the applicant is issued a new registration certificate under the previous number, and when a new dosage form is added, the registration certificate receives a new number.
If the applicant does not reply to a request of the expert organization or authorized body within up to 90 working days, the regulatory review and the variation procedure are terminated. After the variation is made, the product may be manufactured under the previous documents for 180 calendar days from the date of the variation. The exceptions are urgent safety restrictions and a decision of the authorized body of a member state that further manufacture under the previous documents is not possible.
Variations at confirmation of registration
Type IA, IAIN and IB variations may be made at confirmation of registration (re-registration) without a separate variation application. A Type IA variation that does not affect the product information may be made during the regulatory review at confirmation of registration 60 working days or less before the registration certificate expires.
Grouping variations in one application
A separate application and a separate dossier are filed for each variation. There are two exceptions: grouping variations in one application and a document package.
In one application the holder may group Type IA, IAIN, IB and II variations, except a registration extension. A registration extension is included in a group only with variations that are related to it or follow from it. If one variation in the application is rejected, all are rejected.
The procedure type for a group is determined by the most complex variation (table 5).
Table 5. Group of variations in one application and document package
| What is filed | Under the rules of which type | Base period | Maximum period |
|---|---|---|---|
| A group of Type IA and (or) IAIN and at least one Type IB, with no Type II | IB | Regulatory review up to 30 working days | 60 working days |
| A group with at least one Type II variation | II | Regulatory review 60 working days | 80 working days |
| A package of identical Type IA and IAIN variations in the dossiers of one holder’s products | Decision of the reference body on the package | No later than 30 working days from receipt | Extension not specified |
Only Type IA and IAIN are filed by notification, without regulatory review. If an application contains other variations, it undergoes regulatory review under the rules for the corresponding type. So Type IA and IAIN variations that must be filed without regulatory review are filed in a separate application.
A document package may be filed for identical multiple Type IA and IAIN variations in the dossiers of one holder’s products, for variations of the holder itself or of information about it, and for permitted groups of variations whose examples are given in the Variation Rules. There are fourteen such examples. They include one Type II variation with its consequences, variations only in the pharmacovigilance system, variations following the regulatory review of a periodic safety report, and variations arising from an urgent safety restriction.
The package is prepared in the form set by the Variation Rules, with a cover letter in a separate form. The letter is accompanied by an application for each product, documents on payment of the state fee, and amendments to the dossier with supporting documents.
How to assemble the dossier for a variation
The contents of the dossier are defined by the Variation Rules. The cover letter must describe all submitted variations in detail and state the implementation date of each Type IA variation. If a Type IA variation does not require immediate notification, the letter describes all such variations implemented over the last 365 calendar days (12 months) that have not been notified before. The link between a variation and other variations of the same registration is also described in the letter.
The letter is accompanied by an application in the form approved by the Rules for Registration and Regulatory Review, documents on payment of the state fee, amendments to the dossier sections (updated documents) and documents that justify each variation and confirm that the conditions of the classification are met. Where necessary, a document confirming the validity of the version (sequence) of the electronic dossier is added. Documents in another language are filed with an authentic Russian translation.
For an administrative variation, the application is accompanied by confirmation from the authorized body of the reference state that the relevant version of the dossier is valid and has been attached to the electronic dossier. The confirmation is not required in the cases provided for by the Variation Rules.
How much a variation costs
Under the Tax Code of the Russian Federation, the state fee for making a variation to the dossier under Union rules is RUB 150,000 if the variation requires regulatory review and RUB 5,000 if it does not. Type IA and IAIN pass without regulatory review, Type IB and II go to regulatory review. Documents on payment are attached to the application.
The national procedure under 61-FZ costs RUB 490,000 for variations with regulatory review and RUB 5,000 without it. The state fee with regulatory review under Union rules is about 3.3 times lower (490,000 ÷ 150,000 ≈ 3.27).
Rejection of an application for notification-type variations
The authorized body of the reference state rejects an application for notification-type variations within 20 working days of receiving it if the dossier contains variations that are not in the application and are not notification-type. An incomplete set of documents, the absence of documents on payment of the state fee and non-compliance with the classification conditions are also grounds for rejection. Before rejecting, the authorized body may request the missing items within 5 working days.
If the variation does not revise the product information and does not affect the data of the unified register, then when a Type IA variation is rejected, its implementation continues for 365 calendar days from the date it began. A new application that takes the reason for rejection into account is filed before the end of that period.
Editorial corrections and updates to a pharmacopoeial monograph
The authorized body treats the correction of technical errors and typos as editorial if the cover letter (section 1.0 of the common technical document) contains detailed explanations. Without them the correction is treated as an undeclared variation, that is, as unreliable information.
In the application form such corrections are marked as editorial, and the cover letter confirms that they do not change the classification type of the variation. Removing outdated or redundant text is allowed. Removing specification parameters and manufacturing descriptions is not an editorial correction.
An update of a monograph of the Union Pharmacopoeia or of a member state’s pharmacopoeia does not require a separate notification if the dossier cites the current edition. Compliance with the updated monograph must be met within 180 calendar days of its publication.
Change management protocol and design space
The classification of variations provides for agreeing future variations in advance through a post-registration change management protocol. Introduction of a protocol for a medicinal product (code B.II.zh.2) and for an API (code B.I.d.2) is filed as Type II.
Implementation of a variation under an approved protocol is filed as Type IAIN if no additional data are needed and as Type IB if they are needed; for biological products implementation is filed as Type IB (codes B.II.zh.5 and B.I.d.5). Deletion of a protocol is filed as Type IAIN if it is not caused by an unforeseen situation or a failure to meet the specification and does not affect the approved information (codes B.II.zh.3 and B.I.d.3). Significant changes to a protocol are filed as Type II, insignificant ones as Type IB (codes B.II.zh.4 and B.I.d.4).
Introduction of a design space for manufacturing operations or analytical methods is filed as Type II (code B.I.d.1 for an API and code B.II.zh.1 for a medicinal product, other than a biological one). The concepts of Established Conditions and the product lifecycle management plan (PLCM) from the ICH Q12 guideline are not provided for in the Variation Rules.
The registration holder’s obligations between filings
Besides variation applications, the registration holder has obligations with their own deadlines. They are set by the Rules for Registration and Regulatory Review and the Variation Rules and apply regardless of variation applications (table 6).
Table 6. Deadlines for the registration holder’s obligations
| Deadline | Obligation | Where set |
|---|---|---|
| Without delay | Notify the authorized body of the member state of a ban or restriction on the medical use of the product imposed by the bodies of any state on whose market the product is present, and of information that may affect the assessment of the benefit-risk ratio | Rules for Registration and Regulatory Review |
| 20 working days | Provide, at the request of the body, materials confirming a favorable benefit-risk ratio | Rules for Registration and Regulatory Review |
| 10 working days | Provide, at the request of the body, a copy of the pharmacovigilance system master file | Rules for Registration and Regulatory Review |
| As soon as possible, no later than 20 working days | Provide, at the request of the body, information on the implementation of a specific variation | Variation Rules |
| Immediately | Provide, at the request of the body, all information relating to the implementation of a specific variation | Variation Rules |
| 14 working days | After an urgent safety restriction is introduced, submit a position (justification) or a variation application, otherwise the registration certificate is suspended | Variation Rules |
| 120 working days | If obligations were not met for objective reasons at confirmation of registration, update the normative document on quality, SmPC, package leaflet and risk management plan: the period runs from the date of the body’s request | Rules for Registration and Regulatory Review |
A registration holder that introduced an urgent safety restriction on its own initiative notifies all relevant authorities without delay. If the body of a member state does not send an objection within 24 hours of receiving the information, the restriction is considered accepted.
What to do
Determine the variation type by its code in the classification. Find the variation in the classification and check every condition for Type IA. If one is not met, the variation may be filed as Type IB until the classification or a recommendation of the authorized body classifies it as Type II. If the variation is not in the classification, request a recommendation from the authorized body of the reference state before filing and allow for its period: up to 30 working days, and up to 60 if the Expert Committee is consulted.
Record the implementation date and determine the filing deadline. For each variation, check whether it revises the product information or affects the data of the unified register:
if yes, file the application before implementation and implement the variation after the data enter the register;
for Type IA without such an effect, file the application within 365 calendar days of the implementation date;
for Type IAIN, file the application within 20 working days of the implementation date.
Decide how to group variations. File identical Type IA and IAIN variations in the dossiers of several products of one holder as a package in the established form, with a cover letter. File Type IA and IAIN variations that must go without regulatory review in a separate application. Note that the rejection of one variation in a group rejects the whole application.
File the application with the reference state and the states of recognition on time. For Type IB and II, the application to the bodies of the states of recognition is filed within 10 working days after filing in the reference state. Attach the document on payment of the state fee: RUB 5,000 without regulatory review or RUB 150,000 with regulatory review.
Track the deadline for replying to a request and the implementation date. The reply to a request is due in up to 90 working days, after which the regulatory review and the procedure are terminated. Implement Type IB and II only after a positive decision of the reference body, and plan the release under the previous documents within 180 calendar days of the date the variation is made.
Regulatory framework:
1. Decision of the EEC Council No. 78 of 3 November 2016 «On the Rules for Registration and Regulatory Review of Medicines for Medical Use» (as amended on 26 November 2025), including the Rules for Making Variations to the Registration Dossier of a Registered Medicinal Product for Medical Use
2. Decision of the EEC Council No. 93 of 26 November 2025 (title not established)
3. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended on 4 August 2026)
4. Tax Code of the Russian Federation (Part Two) of 5 August 2000 No. 117-FZ (as amended on 4 August 2026)
5. Letter of the Russian Ministry of Health No. 25-6/894 of 29 January 2026 «On the transition period under the procedure for bringing the registration dossiers of medicinal products registered under the rules of member states into line with the requirements of international treaties and acts constituting the law of the EAEU»